Rybrevant Longer-Term Results Show Promising and Durable Responses in Difficult-To-Treat Colorectal Cancer
January 10, 2026
January 10, 2026
RARITAN, New Jersey, Jan. 10 -- Johnson and Johnson Innovative Medicine issued the following news release:
* * *
RYBREVANT(R) (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months
Notable responses were also seen in patients with liver metasta . . .
* * *
RYBREVANT(R) (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months
Notable responses were also seen in patients with liver metasta . . .